Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Durvalumab
How it works
Blocks a protein that helps cancer cells evade the immune system, allowing the immune system to attack and destroy the cancer cells.
Cancer types
Lung Cancer— All patients
Colorectal Cancer— All patients
Pancreatic Cancer— All patients
Ovarian Cancer— All patients
Efficacy
Studies show that durvalumab can improve overall response rate in patients with ovarian cancer, with a response rate of approximately 17%.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| New Cancer Treatment Combination Shows Promise in Lung and Head and Neck Cancers | Lung Cancer | phase-1 | Five (8.3%) patients had objective responses; 31 (51.7%) had stable disease. | Source → |
| Durvalumab as Consolidation for Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Durvalumab Study for Unresectable Lung Cancer in Russia | Lung Cancer | preclinical | — | Source → |
| Combining Chemotherapy and Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | N2 nodal clearance was 73.3% (22/30) after treatment. | Source → |
| Advanced Lung Cancer Treatment Study Underway | Lung Cancer | phase-3 | — | Source → |
| Pancreatic Cancer Treatment Trial | Pancreatic Cancer | phase-1 | — | Source → |
| Trial Tests Cancer Treatments | Colorectal Cancer | phase-2 | — | Source → |
| Durvalumab treatment linked to pneumonitis risk in lung cancer patients | Lung Cancer | observational | — | Source → |
| Durvalumab-Induced Lung Injury Complicated by Human Metapneumovirus Infection | Lung Cancer | observational | — | Source → |
| Timing of Durvalumab Treatment Affects Lung Cancer Survival | Lung Cancer | observational | When considering the timing of durvalumab, no significant survival difference was found when durvalumab was initiated on or before week 4: adjusted HR, 0.81 (95% CI, 0.62 to 1.05, = .07). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer Patients | Ovarian Cancer | phase-2 | PFS36 rates are 47.4% (olaparib priming then olaparib-durvalumab), 48.7% (olaparib-cyclophosphamide then olaparib-durvalumab), and 35.1% (olaparib monotherapy). | Source → |
| Durvalumab and Radiation Therapy Improve Lung Cancer Outcomes | Lung Cancer | phase-3 | The 2- and 3-year local control rates in patients who received total radiation doses > 66 Gy were 80% and 75%, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.